A Gottert, T Abuya, E Proos, I Johnson, NH Dormer, U Foley, G Saul, LB Haddad, DR Friend
{"title":"ACCEPTABILITY OF AND PREFERENCES FOR LONG-ACTING INJECTABLE HORMONAL CONTRACEPTION: RESULTS FROM A NATIONAL ONLINE SURVEY WITH US WOMEN","authors":"A Gottert, T Abuya, E Proos, I Johnson, NH Dormer, U Foley, G Saul, LB Haddad, DR Friend","doi":"10.1016/j.contraception.2024.110635","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>We conducted end-user research to optimize design of a sustained-release microsphere-based etonogestrel long-acting injectable (LAI) in development targeting 6- or 12-month windows of protection, steady hormone dose, and rapid return-to-fertility.</div></div><div><h3>Methods</h3><div>We implemented a national online survey including a discrete choice experiment (DCE) in June-July 2023, with cis-gender women ages 18-44 years. DCE attributes included duration of effectiveness (6/12/24-months), effect on menses, side-effects, and post-use return-to-fertility timing. Data analysis employed mixed-multinomial logit models.</div></div><div><h3>Results</h3><div>1,029 participants completed the survey (mean age 28.6 years, from 49 US states; 30.9% Black/African American; 11.6% Hispanic/Latina; 71.6% nulliparous; 49.0% not wanting a(nother) child). 35.7% currently use birth-control pills (37.4%); 35.7% male condoms; 19.8% withdrawal. In the DCE, participants strongly negatively preferred (in order-of-magnitude): may cause heavier/unpredictable periods, mild headaches/nausea, slight weight-gain, and delayed return-to-fertility (6-12-months vs. 3-months). Participants positively preferred: may cause no period, and shorter/lighter periods. Women significantly preferred 12-month to 6-month duration (p<0.03). Most participants (92.4%) were interested in using the LAI if it had no/minimal side-effects/heavier bleeding and quick return-to-fertility. Two-thirds preferred a 12/24-month duration; one-third a 6-month. Preference for 6-month duration was associated with wanting a child within five years, and higher discomfort with hormones (both p<0.001).</div></div><div><h3>Conclusions</h3><div>While most women report interest in an LAI, interest substantially decreases if it may cause heavier/unpredictable periods, other side-effects, or delayed return-to-fertility. Longer duration (12+ months) is preferred; a 6-month option appears important for women wanting to get pregnant relatively soon, and those concerned about hormones.</div></div>","PeriodicalId":10762,"journal":{"name":"Contraception","volume":"139 ","pages":"Article 110635"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraception","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0010782424003305","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
We conducted end-user research to optimize design of a sustained-release microsphere-based etonogestrel long-acting injectable (LAI) in development targeting 6- or 12-month windows of protection, steady hormone dose, and rapid return-to-fertility.
Methods
We implemented a national online survey including a discrete choice experiment (DCE) in June-July 2023, with cis-gender women ages 18-44 years. DCE attributes included duration of effectiveness (6/12/24-months), effect on menses, side-effects, and post-use return-to-fertility timing. Data analysis employed mixed-multinomial logit models.
Results
1,029 participants completed the survey (mean age 28.6 years, from 49 US states; 30.9% Black/African American; 11.6% Hispanic/Latina; 71.6% nulliparous; 49.0% not wanting a(nother) child). 35.7% currently use birth-control pills (37.4%); 35.7% male condoms; 19.8% withdrawal. In the DCE, participants strongly negatively preferred (in order-of-magnitude): may cause heavier/unpredictable periods, mild headaches/nausea, slight weight-gain, and delayed return-to-fertility (6-12-months vs. 3-months). Participants positively preferred: may cause no period, and shorter/lighter periods. Women significantly preferred 12-month to 6-month duration (p<0.03). Most participants (92.4%) were interested in using the LAI if it had no/minimal side-effects/heavier bleeding and quick return-to-fertility. Two-thirds preferred a 12/24-month duration; one-third a 6-month. Preference for 6-month duration was associated with wanting a child within five years, and higher discomfort with hormones (both p<0.001).
Conclusions
While most women report interest in an LAI, interest substantially decreases if it may cause heavier/unpredictable periods, other side-effects, or delayed return-to-fertility. Longer duration (12+ months) is preferred; a 6-month option appears important for women wanting to get pregnant relatively soon, and those concerned about hormones.
期刊介绍:
Contraception has an open access mirror journal Contraception: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
The journal Contraception wishes to advance reproductive health through the rapid publication of the best and most interesting new scholarship regarding contraception and related fields such as abortion. The journal welcomes manuscripts from investigators working in the laboratory, clinical and social sciences, as well as public health and health professions education.